By implementing Rimidi’s Respiratory Module, which includes integration with Teva’s Digihaler, clinical teams will be well equipped to improve their ability to make personalized, better-informed care decisions for patients with respiratory diseases.
ATLANTA -- March 21, 2023 -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, today announced that Desert Oasis Healthcare (DOHC), a leading regional medical group and Rimidi customer of over eight years, has implemented Rimidi’s new Respiratory Module. Designed to give providers a more complete view of the patient in order to guide treatment decisions for those with respiratory diseases such as chronic obstructive pulmonary disease (COPD) or asthma, the Respiratory Module is enhanced by a collaboration with Teva Pharmaceuticals. Data from Teva’s Digihaler family of digital inhalers is brought into clinical workflows via the Rimidi platform, allowing for efficient management of COPD and asthma within the clinician’s existing electronic health record.
The implementation of the Respiratory Module with DOHC marks a unique collaboration between pharma and a clinical management platform, providing clinicians with more comprehensive data and insights about their patients’ health.
“The ability to have a streamlined, comprehensive view of a patient’s health condition allows for more efficient and personalized management,” said Lucienne Ide, MD, PhD, Founder and CEO of Rimidi. “Rimidi’s Respiratory Module incorporates clinical decision support tools to help clinicians understand potential reasons behind a patient’s uncontrolled asthma, such as not taking their medication, or not taking it properly. These factors are fundamental to achieving good asthma control but have not been easily achieved with the data and systems in place prior to the availability of Teva’s Digihaler.”
DOHC has identified 200 patients with respiratory conditions indicated for treatment with one or more of the products in Teva’s Digihaler System, and who are good candidates for enrollment via the Rimidi platform. This program is led by clinical pharmacists on DOHC’s Population Health and Prescription Management team, who are well positioned to provide patients with the proper medications as well as education and training on inhaler usage and technique.
“Our goal with this implementation is to better monitor patients with respiratory diseases across our population both in the clinic and at home, and to be able to make more personalized care decisions that may lead to more informed treatment plans,” said Lindsey Valenzuela PharmD, APh, BCACP, Administrator of Population Health and Prescription Management at DOHC. “Rimidi’s Respiratory Module, combined with the integration of Teva’s Digihaler system, has helped us quickly identify and assess patients' level of asthma control.”
More than 34 million Americans live with a chronic lung disease, and approximately 25 million people in the U.S. currently have asthma. Understanding more about a patient’s level of asthma control can help identify avoidable complications and an appropriate treatment.
“At Teva, we’re uniquely positioned to help the healthcare ecosystem move toward greater integration of objective health data and create meaningful population-scale solutions to help patients and providers,” said Manny Montalvo, SVP, Head of Digital Health & Innovation at Teva Pharmaceuticals. “We’re excited to help DOHC alongside Rimidi as we seek to utilize the power of technology and therapeutics to be able to predict asthma attacks.”
Created by doctors, Rimidi’s leading clinical management platform empowers healthcare organizations to optimize clinical workflows, enhance patient experiences and achieve quality objectives. By bringing together clinical decision support, remote patient monitoring and patient reported outcomes in a unified, composable, FHIR-based platform, Rimidi supports a broad range of clinical use cases and institutional priorities across large and small healthcare organizations. For more information, visit rimidi.com and follow us on Facebook, Twitter and LinkedIn.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
About Teva Digital Health
Teva aims to be a global leader in personalized, predictive care, continuously investing in platforms and regulatory-compliant systems that will change the nature of digital health as we know it. Teva’s proprietary software platform Digihaler® – developed and maintained in-house by a team of research specialists and programmers – is built into a series of FDA-approved inhalers, currently marketed in the U.S. Learn more at www.Digihaler.com.
About Desert Oasis Healthcare
Formed in 1981 as one of the first medical groups in the desert communities of southern California, Desert Oasis Healthcare (DOHC) continues to advance with changes in the healthcare market. DOHC provides primary and immediate care, home health, palliative care, and other services to more than 60,000 members/patients living in the greater Coachella Valley and the Morongo Basin of Riverside and San Bernardino counties. The multidisciplinary and comprehensive care programs of DOHC are committed to educating individuals on preventative health care in their daily lives, reflected in the DOHC motto, "Your Health. Your Life. Our Passion." For more information, visit http://www.mydohc.com.
Recent News & Insights
During 2023, we’ve seen labor shortages in hospitals and healthcare systems drive some of the …
On November 2, The Centers for Medicare and Medicaid Services (CMS) released the 2024 Final …